Table 2.
Anti-IGF receptor therapies in pre-clinical development.
| Agent | Description | Company | Status/Notes | Ref |
|---|---|---|---|---|
| BVP.51004 | Tyrosine kinase inhibitor, non-ATP competitive | Biovitrium | Cyclolignan PPP. Downregulated IGF-1R, without insulin receptor inhibition. Development status not disclosed. | [63] |
| rhIGFBP3 | IGF binding protein | Insmed | Awaiting clinical investigations | |
| NVP-ADW742 | Tyrosine kinase inhibitor, reversible ATP competitive | Novartis | No clinical investigations currently ongoing. | [36] |
| NVP-AEW541 | Tyrosine kinase inhibitor, reversible ATP competitive | Novartis | No clinical investigations currently ongoing. | [35] |
| BMS-536924 | Tyrosine kinase inhibitor, reversible ATP competitive | Bristol-Myers Squibb | IGF-1R inhibitor BMS-754807 currently undergoing phase I investigations | [2, 74] |
| BMS-554417 | Tyrosine kinase inhibitor, reversible ATP competitive | Bristol-Myers Squibb | IGF-1R inhibitor BMS-754807 currently undergoing phase I investigations | [38] |
| ANT-429 | Pharmacophore | Antrya | Preclinical investigations | |
| ATL-1101 | Antisense oligonucleotides | Asntisense Therapeutics | Beginning clinical investigations for dermatologic conditions and cancer. | |
| Tyrphostin AG1024 | Tyrosine kinase inhibitor | – | Not in clinical development | [75] |
| α-IR3 | Mouse monoclonal antibody | – | Not in clinical development | [76] |